May 27 2022




Recommendations

During maternal treatment with chlorpromazine, some infants develop drowsiness, although this does not seem to affect the baby, unless it is used in combination with other drugs, particularly haloperidol.

If considered necessary to use chlorpromazine, should be monitored closely the evolution of the infant, in a particular way when other drugs are used simultaneously.

In general, there seem to be any symptoms in infants attributable to the drug. There is no parallel between maternal dose and the levels in milk or infant. Some babies seem to sleep more than usual, but there are some known cases of drowsiness and even lethargy, which require stopping exposure to the drug.

In a longitudinal study of four children whose mothers received chlorpromazine, there was a decrease in psychomotor development indicators in two babies whose mothers were also taking haloperidol. In contrast, the other two babies, not exposed to other antipsychotic, were developed normally.

Chlorpromazine can produce galactorrhea, having been used to stimulate milk production, although it is presently preferred other drugs for this purpose.

Warning of the manufacturer:

Chlorpromazine is excreted in breast milk. Because serious adverse effects may occur in the infant, the physician must assess the substitution of breastfeeding by artificial feeding or discontinuation of chlorpromazine.

Updated:15.04.08